Current and former employees are suing JPMorgan, alleging that it allows inflated drug prices through its partnership with its pharmacy benefit manager, CVS Caremark.
After turning over more than 1,300 documents to the Federal Trade Commission, the fast food giant is turning its attention to subpoenas from pharmacy benefit managers the agency accuses of artificially inflating insulin prices.
The company put out a statement on Friday rejecting the allegations, but the Wall Street Journal article caused a 7.17% drop in the price of its stock.
The focus on comprehensive family wellbeing benefits is reshaping the workplace, offering employers a powerful tool to attract and retain top talent while mitigating rising health care costs.